Functional drivers of resistance to anti-CD19 CAR-T cell therapy in diffuse large B cell lymphoma

References

• Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709–2720. doi:10.1182/blood-2011-10-384388
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–549. doi:10.1200/JCO.2014.56.2025
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. doi:10.1056/NEJMoa1707447
   PubMed Web of Science ®Google Scholar
• Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2023;402(10402):641–654. doi:10.1016/S0140-6736(20)31366-0
   PubMedGoogle Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. doi:10.1056/NEJMoa1804980
   PubMed Web of Science ®Google Scholar
• Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640–654. doi:10.1056/NEJMoa2116133
   PubMed Web of Science ®Google Scholar
• Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294–2308. doi:10.1016/S0140-6736(22)00662-6
   PubMed Web of Science ®Google Scholar
• Westin JR, Oluwole OO, Kersten MJ, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389(2):148–157. doi:10.1056/NEJMoa2301665
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38(27):3119–3128. doi:10.1200/JCO.19.02104
   PubMed Web of Science ®Google Scholar
• Bachy E, Le Gouill S, Di Blasi R, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28(10):2145–2154. doi:10.1038/s41591-022-01969-y
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011(1):498–505. doi:10.1182/asheducation-2011.1.498
   PubMed Web of Science ®Google Scholar
• Spiegel JY, Dahiya S, Jain MD, et al. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood. 2021;137(13):1832–1835. doi:10.1182/blood.2020006245
   PubMed Web of Science ®Google Scholar
• Locke FL, Rossi JM, Neelapu SS, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(19):4898–4911. doi:10.1182/bloodadvances.2020002394
   PubMed Web of Science ®Google Scholar
• Frank MJ, Hossain NM, Bukhari A, et al. Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial. J Clin Oncol. 2021;39(27):3034–3043. doi:10.1200/JCO.21.00377
   PubMed Web of Science ®Google Scholar
• Sworder BJ, Kurtz DM, Alig SK, et al. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell. 2023;41(1):210–225.e5. doi:10.1016/j.ccell.2022.12.005
   PubMed Web of Science ®Google Scholar
• Jain MD, Ziccheddu B, Coughlin CA, et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 2022;140(5):491–503. Published online blood.2021015008. doi:10.1182/blood.2021015008
   PubMed Web of Science ®Google Scholar
• Abramson JS, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675–1684. doi:10.1182/blood.2022018730
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690. doi:10.1038/s41591-018-0016-8
   PubMed Web of Science ®Google Scholar
• Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551–568.e14. doi:10.1016/j.ccell.2020.03.015
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407. doi:10.1056/NEJMoa1801445
   PubMed Web of Science ®Google Scholar
• Rossi J, Paczkowski P, Shen YW, et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood. 2018;132(8):804–814. doi:10.1182/blood-2018-01-828343
   PubMed Web of Science ®Google Scholar
• Deng Q, Han G, Puebla-Osorio N, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020;26(12):1878–1887. doi:10.1038/s41591-020-1061-7
   PubMed Web of Science ®Google Scholar
• Worel N, Grabmeier-Pfistershammer K, Kratzer B, et al. The frequency of differentiated CD3 + CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma. Front Immunol. 2022;13:1004703. Accessed May 10, 2023 doi:10.3389/fimmu.2022.1004703
   PubMedGoogle Scholar
• Good Z, Spiegel JY, Sahaf B, et al. Post-infusion CAR TReg cells identify patients resistant to CD19-CAR ­therapy. Nat Med. 2022;28(9):1860–1871. doi:10.1038/s41591-022-01960-7
   PubMed Web of Science ®Google Scholar
• Faramand R, Jain M, Staedtke V, et al. Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-Cell lymphoma treated with axicabtagene ciloleucel. Clin Cancer Res. 2020;26(18):4823–4831. doi:10.1158/1078-0432.CCR-20-1434
   PubMed Web of Science ®Google Scholar
• Scholler N, Perbost R, Locke FL, et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med. 2022;28(9):1872–1882. doi:10.1038/s41591-022-01916-x
   PubMed Web of Science ®Google Scholar
• Chen PH, Lipschitz M, Weirather JL, et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight. 2020;5(12):e134612. doi:10.1172/jci.insight.134612
   PubMed Web of Science ®Google Scholar
• Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282–1295. doi:10.1158/2159-8290.CD-15-1020
   PubMed Web of Science ®Google Scholar
• Domizi P, Sarno J, Jager A, et al. Ikaros mediates antigen escape following CD19 CAR T cell therapy in r/r B-ALL. Blood. 2021;138(Supplement 1):613–613. doi:10.1182/blood-2021-151002
   PubMedGoogle Scholar
• Witkowski MT, Lee S, Wang E, et al. NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia. Nat Immunol. 2022;23(10):1424–1432. doi:10.1038/s41590-022-01314-y
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen X, Tian Y, et al. Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy. J Immunother Cancer. 2020;8(2):e001150. doi:10.1136/jitc-2020-001150
   PubMed Web of Science ®Google Scholar
• Spiegel JY, Patel S, Muffly L, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27(8):1419–1431. doi:10.1038/s41591-021-01436-0
   PubMed Web of Science ®Google Scholar
• Plaks V, Rossi JM, Chou J, et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood. 2021;138(12):1081–1085. doi:10.1182/blood.2021010930
   PubMed Web of Science ®Google Scholar
• Shouval R, Alarcon Tomas A, Fein JA, et al. Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-Chimeric antigen receptor T-Cell therapy. J Clin Oncol. 2022;40(4):369–381. doi:10.1200/JCO.21.02143
   PubMed Web of Science ®Google Scholar
• Porpaczy E, Wohlfarth P, Königsbrügge O, et al. Influence of TP53 mutation on survival of diffuse large B-cell lymphoma in the CAR T-cell era. Cancers. 2021;13(22):5592. doi:10.3390/cancers13225592
   PubMed Web of Science ®Google Scholar
• Hill BT, Roth CJ, Kositsky R, et al. Impact of molecular features of diffuse large B-cell lymphoma on treatment outcomes with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Blood. 2021;138(Supplement 1):165–165. doi:10.1182/blood-2021-145764
   Google Scholar
• Upadhyay R, Boiarsky JA, Pantsulaia G, et al. A critical role for Fas-mediated off-Target tumor killing in T-cell immunotherapy. Cancer Discov. 2021;11(3):599–613. doi:10.1158/2159-8290.CD-20-0756
   PubMed Web of Science ®Google Scholar
• Cherng HJJ, Sun R, Sugg B, et al. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood. 2022;140(5):504–515. doi:10.1182/blood.2022015601
   PubMed Web of Science ®Google Scholar
• Duncavage EJ, Schroeder MC, O'Laughlin M, et al. Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers. N Engl J Med. 2021;384(10):924–935. doi:10.1056/NEJMoa2024534
   PubMed Web of Science ®Google Scholar
• Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021;39(18):1959–1970. doi:10.1200/JCO.20.03175
   PubMed Web of Science ®Google Scholar
• Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with ­relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055–1065. doi:10.1016/S1470-2045(22)00335-7
   PubMed Web of Science ®Google Scholar
• Roddie C, Lekakis LJ, Marzolini MAV, et al. Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma. Blood. 2023;141(20):2470–2482. doi:10.1182/blood.2022018598
   PubMed Web of Science ®Google Scholar